

## **Rapid Reaction: ANNEXA-4 Final Study Report**

Special Guest: Brian Gilbert, PharmD, MBA, BCCCP, BCPS, FCCM

### **ANNEXA-4 Publications**

Milling TJ, Middeldorp S, Xu L, et al. Final Study Report of Andexanet Alfa for Major Bleeding with Factor Xa Inhibitors. *Circulation*. 2023 Feb 20. doi:

10.1161/CIRCULATIONAHA.121.057844. Online ahead of print.

<https://pubmed.ncbi.nlm.nih.gov/36802876/>

Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. *N Engl J Med* 2019; 380: 1326-35.

<https://pubmed.ncbi.nlm.nih.gov/30730782/>

Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. *N Engl J Med* 2016; 375: 1131-41.

<https://pubmed.ncbi.nlm.nih.gov/27573206/>

### **Articles Referenced**

Panos NG, Cook AM, John S, et al. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results from a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. *Circulation*. 2020; 141(21): 1681-1689.

<https://pubmed.ncbi.nlm.nih.gov/32264698/>

Giffard-Quillon L, Desmurs-Clavel H, Grange C, et al. Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation? *Thromb J* 2020; 18: 15. <https://pubmed.ncbi.nlm.nih.gov/32855623/>

Cooksey GE, Hamilton LA, McMillen JC, et al. Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries. *Neurocrit Care*. 2022; 37(2): 471-478. <https://pubmed.ncbi.nlm.nih.gov/35624388/>